arsenic trioxide has been researched along with bibr 1532 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Hezave, K; Kazerani, M; Rostami, M; Zaker, F | 1 |
| Bashash, D; Ghaffari, SH; Kabuli, M; Kashani, B; Mousavi, SA; Nasrollahzadeh, A; Zaghal, A; Zandi, Z | 1 |
2 other study(ies) available for arsenic trioxide and bibr 1532
| Article | Year |
|---|---|
BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
Topics: Aminobenzoates; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Naphthalenes; Oxides; Telomerase | 2013 |
Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-κB signaling pathway.
Topics: Aminobenzoates; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; MCF-7 Cells; Naphthalenes; NF-kappa B; Signal Transduction | 2020 |